| Ernest Bloom, MD | |
|
501 S Shore Ctr W, 103a, Alameda, CA 94501-5762 | |
| (510) 227-7028 | |
| (510) 274-7119 |
| Full Name | Ernest Bloom |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 40 Years |
| Location | 501 S Shore Ctr W, Alameda, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306941620 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Csi Medical Group | 5890916845 | 103 |
News Archive
A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.S. Food and Drug Administration.
To keep the body safe, the immune system enlists more than one form of protection. A circulating task force of immune system cells monitors the body's periphery, and sends information back to field command centers — the lymph nodes — located at pivotal traffic points.
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego.
A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010."We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application."
› Verified 8 days ago
| Entity Name | Csi Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871909804 PECOS PAC ID: 5890916845 Enrollment ID: O20141016001930 |
News Archive
A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.S. Food and Drug Administration.
To keep the body safe, the immune system enlists more than one form of protection. A circulating task force of immune system cells monitors the body's periphery, and sends information back to field command centers — the lymph nodes — located at pivotal traffic points.
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego.
A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010."We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ernest Bloom, MD 501 S Shore Ctr W, 103a, Alameda, CA 94501-5762 Ph: (510) 227-7028 | Ernest Bloom, MD 501 S Shore Ctr W, 103a, Alameda, CA 94501-5762 Ph: (510) 227-7028 |
News Archive
A first-of-its-kind contraceptive developed at the University of Illinois Chicago has been approved by the U.S. Food and Drug Administration.
To keep the body safe, the immune system enlists more than one form of protection. A circulating task force of immune system cells monitors the body's periphery, and sends information back to field command centers — the lymph nodes — located at pivotal traffic points.
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego.
A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010."We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application."
› Verified 8 days ago